# Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

> **NCT01999101** · PHASE2 · COMPLETED · sponsor: **Phenex Pharmaceuticals AG** · enrollment: 12 (actual)

## Conditions studied

- Non Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Px-104

## Key facts

- **NCT ID:** NCT01999101
- **Lead sponsor:** Phenex Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-01
- **Final completion:** 2016-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01999101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01999101, "Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01999101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*